CABA Overview
Upcoming Projects (CABA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CABA)
-
Discussing the phase 1/2 clinical trial data on KYV-101 and CABA-201, two CAR-T therapies being developed for the treatment of autoimmune diseases.
Tickers: KYTX, CABA
Executed On: Sep 04, 2024 at 01:00 PM EDT -
Discussing the potential of anti-CD19 CAR T Cells for the treatment of myasthenia gravis.
Tickers: CABA, KYTX
Executed On: Aug 14, 2024 at 04:00 PM EDT -
Discussing the potential of CD19 targeted therapies in systemic lupus erythematosus (SLE)
Tickers: AMGN, CGEM, ELYM, CABA
Executed On: Jul 19, 2024 at 12:30 PM EDT -
A Second View: Discussing CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
Ticker: CABA
Executed On: Jan 24, 2023 at 02:00 PM EST -
A discussion of CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
Ticker: CABA
Executed On: Nov 17, 2022 at 12:00 PM EST
Expired Projects (CABA)
-
Showcasing Cabaletta Bio's Progress: Insights into the Phase 1/2 RESET Trials for CABA-201
Ticker: CABA
Execute By: Aug 31, 2024
Upcoming & Overdue Catalysts (CABA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CABA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
